Leiden, The Netherlands, August 23, 2006 - Paul Vermeij has joined Dutch biotechnology company Crucell (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) as Director of Investor Relations and Corporate Communications.
Paul (47) brings with him experience gained over a 23-year career in financial and corporate communications. He worked as Director of Corporate Communications at Andersen (later Deloitte) before joining Crucell from Berenschot Communicatie, where he worked as a senior managing consultant.
About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.
For further information please contact:
Crucell N.V. Paul Vermeij Director Investor Relations and Corporate Communications Tel. +31-(0)71-524 8718 email@example.com